Blood transfusion · patients with upper gastrointestinal bleeding
It is very uncertain whether tranexamic acid changes transfusion Number needing blood transfusion compared with placebo (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Participants with Crohn's disease in remission
Methotrexate probably leads to higher proportion of patients maintaining clinical remission compared with placebo (moderate certainty).
3 findings from 1 review
RR 1.57 [1.1, 2.23]
2 studies · 98 participants
Moderate
RR 1.67 [1.05, 2.67]
1 study · 76 participants
Moderate
RR 1.35 [0.86, 2.12]
1 study · 22 participants
Low
Maintenance of clinical remission · maintenance of remission in Crohn's disease
Methotrexate + infliximab showed no clear difference in proportion of patients maintaining remission compared with infliximab +/‐ placebo (low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Clinical relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbation of IBD · IBD patients
Etoricoxib showed no clear difference in exacerbation of IBD compared with placebo (low certainty).
1 finding from 1 review
Exacerbation of ulcerative colitis · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in exacerbation of ulcerative colitis compared with placebo (low certainty).
1 finding from 1 review
GI adverse events · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in GI adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · patients with induction of remission in ulcerative colitis
Trichuris suis eggs showed no clear difference in clinical remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement at 12 weeks · patients with induction of remission in ulcerative colitis
Trichuris suis eggs showed no clear difference in clinical improvement at 12 weeks compared with placebo (low certainty).
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA may leads to higher symptomatic remission compared with placebo (low certainty).
1 finding from 1 review
Relapse at 6 months Clinical Disease Activty Index more than 42 · Maintenance of remission in ulcerative colitis
Curcumin showed no clear difference in relapse at 6 months Clinical Disease Activty Index more than 42 compared with placebo (low certainty).
1 finding from 1 review
Relapse at 12 months Clinical Disease Activty Index more than 42 · Maintenance of remission in ulcerative colitis
Curcumin showed no clear difference in relapse at 12 months Clinical Disease Activty Index more than 42 compared with placebo (low certainty).
1 finding from 1 review
Disease activity · Maintenance of remission in ulcerative colitis
1 finding from 1 review
Endoscopic Index at 6 months Endoscopic Index9. Scale from: 1 to 4. · Maintenance of remission in ulcerative colitis
1 finding from 1 review